中关村接待投资者调研：集采有望实现“以价换量”目标

Group 1: Company Overview - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. (referred to as "Zhongguancun") held an investor relations activity on September 15, where executives discussed the company's main business development and market trends with over ten institutional investors [1] - Zhongguancun's subsidiary, Duoduo Pharmaceutical Co., Ltd., won a centralized procurement bid for its Siberian Ginseng Injection, effective until December 31, 2027 [1] Group 2: Sales Performance and Market Strategy - The management indicated that sales revenue for Siberian Ginseng Injection is expected to grow by 38% year-on-year in the first half of 2025, although significant volume increases have not yet materialized due to delays in the procurement execution period [1] - The management expressed optimism that the product could achieve the goal of "volume through price" as the procurement process deepens and hospital development progresses [2] Group 3: Product Development - Zhongguancun's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., is developing two differentiated products for treating Attention Deficit Hyperactivity Disorder (ADHD), including a chewable sustained-release tablet and an oral sustained-release suspension [2] - These products are designed to improve medication adherence among children, particularly those with swallowing difficulties, offering more flexible dosing options compared to traditional sustained-release tablets [2] Group 4: New Market Ventures - Zhongguancun has made significant strides in the green building materials sector, successfully winning a bid for a wind power mixed tower project, marking its entry into the wind power market [3] - The company aims to establish a green production system focused on low energy consumption, low emissions, and high performance [4]